The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Sumatriptan-Naproxen for Acute Treatment of Migraine: A Randomized Trial
Abstract
CONTEXT: Multiple pathogenic mechanisms may be involved in generating the migraine symptom complex, and multimechanism-targeted therapy may confer advantages over monotherapy. OBJECTIVE: To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate and naproxen sodium relative to efficacy and safety of each monotherapy and placebo for the acute treatment of migraine. DESIGN, SETTING, AND PARTICIPANTS: Two replicate, randomized, double-blind, single-attack, parallel-group studies conducted among 1461 (study 1) and 1495 (study 2) patients at 118 US clinical centers who were diagnosed as having migraine and received study treatment for a moderate or severe migraine attack. INTERVENTIONS: Patients were randomized in a 1:1:1:1 ratio to receive a single tablet containing sumatriptan, 85 mg, and naproxen sodium, 500 mg; sumatriptan, 85 mg (monotherapy); naproxen sodium, 500 mg (monotherapy); or placebo, to be used after onset of a migraine with moderate to severe pain. MAIN OUTCOME MEASURES: Primary outcome measures included the percentages of patients with headache relief 2 hours after dosing, absence of photophobia, absence of phonophobia, and absence of nausea for the comparison between sumatriptan-naproxen sodium and placebo, and the percentages of patients with sustained pain-free response for the comparison between sumatriptan-naproxen sodium and each monotherapy. RESULTS: Sumatriptan-naproxen sodium was more effective than placebo for headache relief at 2 hours after dosing (study 1, 65% vs 28%; P<.001 and study 2, 57% vs 29%; P<.001), absence of photophobia at 2 hours (58% vs 26%; P<.001 and 50% vs 32%; P<.001), and absence of phonophobia at 2 hours (61% vs 38%; P<.001 and 56% vs 34%; P<.001). The absence of nausea 2 hours after dosing was higher with sumatriptan-naproxen sodium than placebo in study 1 (71% vs 65%; P = .007), but in study 2 rates of absence of nausea did not differ between sumatriptan-naproxen sodium and placebo (65% vs 64%; P = .71). For 2- to 24-hour sustained pain-free response, sumatriptan-naproxen sodium was superior at P<.01 (25% and 23% in studies 1 and 2, respectively) to sumatriptan monotherapy (16% and 14% in studies 1 and 2), naproxen sodium monotherapy (10% and 10% in studies 1 and 2), and placebo (8% and 7% in studies 1 and 2). The incidence of adverse events was similar between sumatriptan-naproxen sodium and sumatriptan monotherapy. CONCLUSION: Sumatriptan, 85 mg, plus naproxen sodium, 500 mg, as a single tablet for acute treatment of migraine resulted in more favorable clinical benefits compared with either monotherapy, with an acceptable and well-tolerated adverse effect profile. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT00434083 (study 1); NCT00433732 (study 2).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Headache Disorders: 2nd edition
Olesen, J., Goadsby, P., & Steiner, T. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00590-8 · Cited by 5,049
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Multiple Comparison Procedures
(2013) · An Introduction to Statistical Concepts · doi:10.4324/9780203137819-17 · Cited by 2,109
Migraine — Current Understanding and Treatment
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010917 · Cited by 1,918
An association between migraine and cutaneous allodynia
Burstein, R., Yarnitsky, D., Goor-Aryeh, I., Ransil, B. J., & Bajwa, Z. H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200005)47:5<614::aid-ana9>3.0.co;2-n · Cited by 1,016
Ferrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06711-3 · Cited by 987
Modified Sequentially Rejective Multiple Test Procedures
Shaffer, J. P. (1986) · Journal of the American Statistical Association · doi:10.1080/01621459.1986.10478341 · Cited by 806
Cited by
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study
Tassorelli, C., Grazzi, L., de Tommaso, M., Pierangeli, G., Martelletti, P., Rainero, I., Dorlas, S., Geppetti, P., Ambrosini, A., Sarchielli, P., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005857 · Cited by 254
Moore, R. A., Derry, C. J., Derry, S., Straube, S., & McQuay, H. J. (2012) · European Journal of Pain · doi:10.1016/j.ejpain.2011.08.009 · Cited by 63
A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches
Peck, J., Urits, I., Zeien, J., Hoebee, S., Mousa, M., Alattar, H., Kaye, A. D., & Viswanath, O. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00852-0 · Cited by 37
Metadata
- Authors
- Brandes, J. L., Kudrow, D., Stark, S. R., O’Carroll, C. P., Adelman, J. U., O’Donnell, F. J., Alexander, W. J., Spruill, S. E., Barrett, P. S., & Lener, S. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-04-04
- Volume
- 297
- Issue
- 13
- Pages
- 1443-54
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2041898141
- Cited by
- 276
- References
- 25
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sumatriptan-Naproxen for Acute Treatment of Migraine: A Randomized Trial. https://app.cochat.ai/papers/10.1001/jama.297.13.1443
- The paper
- Brandes, J. L., Kudrow, D., Stark, S. R., O’Carroll, C. P., Adelman, J. U., O’Donnell, F. J., Alexander, W. J., Spruill, S. E., Barrett, P. S., & Lener, S. E. (2007). Sumatriptan-Naproxen for Acute Treatment of Migraine: A Randomized Trial. JAMA. https://doi.org/10.1001/jama.297.13.1443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.